{"filing":{"accession_number":"0001140361-26-029841","cik":"0001162194","ticker":"LAB","company_name":"STANDARD BIOTOOLS INC.","form":"8-K","filing_date":"2026-07-28","report_date":"2026-07-24","primary_document":"ef20078901_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1162194/000114036126029841/ef20078901_8k.htm"},"events":[{"id":20936,"run_id":18857,"accession_number":"0001140361-26-029841","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"Standard BioTools entered into multiple material M\u0026A transactions: (1) a Termination, Waiver and Release Agreement with Illumina for $30 million cash to waive earnout and royalty obligations from the SomaLogic acquisition, (2) a Share and Asset Purchase Agreement to sell its mass cytometry business (CyTOF and Hyperion product lines) to Multiplex Bio for up to $10 million, and (3) a pending merger with Treeline Biosciences (Form S-4 filed July 20, 2026; HSR early termination received July 21, 2026). These transactions materially affect the company's asset base, cash position, and business structure.","company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","filing_date":"2026-07-28","form":"8-K","submitted_at":null,"items":[{"id":20444,"accession_number":"0001140361-26-029841","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Standard BioTools entered into two material definitive agreements on July 24 and July 28, 2026: (1) a Termination, Waiver and Release Agreement with Illumina resulting in a $30 million cash payment in exchange for waiving earnout and royalty obligations, and (2) a Share and Asset Purchase Agreement to sell its mass cytometry business to Multiplex Bio for up to $10 million. Both transactions materially affect the company's asset base, cash position, and business structure, particularly in the context of the pending Treeline merger. The sale of the mass cytometry business (CyTOF and Hyperion product lines) constitutes a material disposition of business assets.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T12:21:41.696293+00:00","company_name":"","ticker":null,"filing_date":""},{"id":20445,"accession_number":"0001140361-26-029841","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses multiple material M\u0026A transactions: (1) an agreement to sell the Mass Cytometry business to Multiplex Bio (valued at up to $10 million with a working capital loan), (2) a $30 million buyout of contingent payments from Illumina related to the SomaLogic acquisition, and (3) the pending merger with Treeline Biosciences (with Form S-4 filed July 20, 2026 and HSR early termination received July 21, 2026). The Treeline transaction is the principal transaction, with the Mass Cytometry sale and Illumina buyout being ancillary transactions to facilitate it. These are material dispositions and acquisitions that would significantly affect investor assessment of the company's business composition and financial position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T12:21:41.696293+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":20444,"accession_number":"0001140361-26-029841","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Standard BioTools entered into two material definitive agreements on July 24 and July 28, 2026: (1) a Termination, Waiver and Release Agreement with Illumina resulting in a $30 million cash payment in exchange for waiving earnout and royalty obligations, and (2) a Share and Asset Purchase Agreement to sell its mass cytometry business to Multiplex Bio for up to $10 million. Both transactions materially affect the company's asset base, cash position, and business structure, particularly in the context of the pending Treeline merger. The sale of the mass cytometry business (CyTOF and Hyperion product lines) constitutes a material disposition of business assets.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T12:21:41.696293+00:00","company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","filing_date":"2026-07-28"},{"id":20445,"accession_number":"0001140361-26-029841","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"The filing discloses multiple material M\u0026A transactions: (1) an agreement to sell the Mass Cytometry business to Multiplex Bio (valued at up to $10 million with a working capital loan), (2) a $30 million buyout of contingent payments from Illumina related to the SomaLogic acquisition, and (3) the pending merger with Treeline Biosciences (with Form S-4 filed July 20, 2026 and HSR early termination received July 21, 2026). The Treeline transaction is the principal transaction, with the Mass Cytometry sale and Illumina buyout being ancillary transactions to facilitate it. These are material dispositions and acquisitions that would significantly affect investor assessment of the company's business composition and financial position.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-28T12:21:41.696293+00:00","company_name":"STANDARD BIOTOOLS INC.","ticker":"LAB","filing_date":"2026-07-28"}]}